eXoZymes, Inc.
EXOZ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$35.77M
Close$
$0.21
94.8% downside
Current Fair Value
94.8% downsideOvervalued by 94.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $35.77 Million |
|---|---|
| Enterprise Value | $30.86 Million |
| Earnings per Share | $-1.09 |
| Beta | 3.19 |
| Outstanding Shares | 8,660,246 |
Return
| Return on Equity | -278.89% |
|---|---|
| Return on Assets | -127.67% |
| Return on Invested Capital | -35.00% |
Valuation & Multiples
| P/E Ratio | -3.44 |
|---|---|
| PEG | -15.67 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.85 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.21%▼ 1.23% |
|---|---|
| Total Invested | $104,946▼ 90.01% |
| Investors Holding | 2▼ 8.00% |
About eXoZymes, Inc.
32 employees
CEO: Michael Heltzen
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Tech...